Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
March 31, 2021 at 05:36 pm IST
Share
Huapont Life Sciences Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 10,876.361 million compared to CNY 10,091.370 million a year ago. Operating income was CNY 1,194.861 million compared to CNY 1,155.966 million a year ago. Net income was CNY 651.730 million compared to CNY 620.205 million a year ago. Basic earnings per share from continuing operations was CNY 0.33 compared to CNY 0.31 a year ago.
HUAPONT LIFE SCIENCES CO., LTD. is a China-based company principally engaged in the research and development, manufacture and sales of pesticide chemical products. The Company operates through three segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sales of skin pharmaceuticals, antituberculous pharmaceuticals and other manufactured products. Its products include fleroxacin and ambroxol hydrochloride for injection, and lecithin-bound iodine capsules, among others. The Pesticide Chemical segment is engaged in the production and sales of pesticides and other fine chemicals, including herbicides, bactericides and insecticides, among others. The Bulk Drug segment is engaged in the research and development and manufacture of bulk drugs and medical intermediates. The Company is also engaged in the provision of travel services, the sales of tea and the provision of technical services, among others.
HUAPONT LIFE SCIENCES CO.,LTD 
